Modulation of the immune response

Patent metadata

Field	Value
Publication number	US-9895440-B2
Application number	US-201414554536-A
Country	US
Kind code	B2
Filing date	Nov 26, 2014
Priority date	Nov 20, 2007
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

Methods for increasing the numbers of regulatory T cells (Treg), e.g., in a population of T cells or in a patient.

First claim

What is claimed is:

1. A method for increasing the number of CD4/CD25/Foxp3-expressing T regulatory (Treg) cells in a population of T cells, the method comprising contacting the population of T cells with a sufficient amount of a composition comprising a ligand that binds specifically to an aryl hydrocarbon receptor (AHR) transcription factor, and an antibody that selectively binds to an antigen present on a T cell, a B cell, a dendritic cell, or a macrophage, wherein the antibody and the ligand are linked to a biocompatible gold nanoparticle, wherein the method results in an increase in the number and/or activity of regulatory Treg cells.

2. The method of claim 1 , wherein the ligand is a small molecule that competes for binding to the AHR competitively with 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) and activates AHR-dependent signaling.

3. The method of claim 1 , wherein the ligand is 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD).

4. The method of claim 1 , wherein the ligand is tryptamine (TA).

5. The method of claim 1 , wherein the composition further comprises a monoamine oxidase inhibitor.

6. The method of claim 5 , wherein the monoamine oxidase inhibitor is tranylcypromine.

7. The method of claim 1 , wherein the ligand is 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE).

8. The method of claim 1 , wherein the ligand is 6 formylindolo[3,2 b]carbazole (FICZ).

9. The method of claim 1 , wherein the biocompatible gold nanoparticle is pegylated.

10. The method of claim 1 , wherein the population of T cells comprises naïve T cells or CD4+CD62 ligand+ T cells.

11. The method of claim 1 , further comprising administering the Treg cells to a subject suffering from an autoimmune disorder, in an amount sufficient to improve or ameliorate a symptom of the disorder.

12. The method of claim 1 , wherein the population of T cells is in a living mammalian subject, and the method comprises administering the composition to the subject.

13. The method of claim 12 , wherein the subject has multiple sclerosis.

14. The method of claim 12 , comprising administering the composition orally.

15. The method of claim 12 , comprising administering the composition intravenously.

Assignees

• Brigham & Womens Hospital Inc

Inventors

• Weiner Howard
• Quintana Francisco J

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K31/407

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title